Product Overview
Structure
1 ml of the solution contains at least 10,000 IU of recombinant alpha-2 human interferon.
pharmachologic effect
Farmgroup:
MIBP is a cytokine.
Farm action:
The drug has immunomodulatory, anti-inflammatory and antiviral effects.
Pharmacokinetics:
With intranasal administration, the concentration of the active substance achieved in the blood is significantly lower than the detection limit (the detection limit of interferon alpha-2b is 1-2 IU / ml) and has no clinical significance.
Indications
Prevention and treatment of influenza and SARS in children from birth and adults, including pregnant women.
Pregnancy and lactation
It is approved for use during the entire period of pregnancy.
Contraindications
- Individual intolerance to interferon preparations and the components that make up the preparation of Grippferon.
- Severe forms of allergic diseases.
Side effects
Allergic reactions.
How to take, course of administration and dosage
At the first signs of the disease, they are instilled into the nose for 5 days:
children under 1 year old - 1 drop in each nasal passage 5 times a day (single dose of 1,000 IU, daily dose of 5,000 IU);
children from 1 to 3 years old - 2 drops in each nasal passage 3-4 times a day (single dose 2000 ME, daily - 6000-8000 ME);
children from 3 to 14 years old - 2 drops in each nasal passage 4-5 times a day (single dose 2000 ME, daily dose 8000-10000 ME);
adults - 3 drops in each nasal passage 5-6 times a day (single dose of 3,000 ME, daily dose of 15,000 to 18,000 ME).
For the purpose of prevention (SARS and influenza): upon contact with the patient and / or upon hypothermia, the drug is instilled in an age-related dosage 2 times a day for 5-7 days. If necessary, preventive courses are repeated; with a seasonal increase in the incidence of the drug, the drug is instilled at an age-specific dosage in the morning after 1-2 days.
After each instillation, it is recommended to massage the fingers with the wings of the nose for several minutes to evenly distribute the drug in the nasal cavity.
Special instructions
The simultaneous use of intranasal vasoconstrictor drugs is not recommended due to the strengthening of the drying effect on the nasal mucosa.
Release form
Drops for intranasal use.
